Last week, biopharmaceutical company Gilead Sciences travelled to Capitol Hill to brief members of Congress on the cost of its hepatitis C drug Sovaldi, according to a Jewish Times report.
Sovaldi is currently priced at approximately $1,000 a pill, a total of $84,000 or more for a full course of treatment. But, Gilead Sciences intends to release a new interferon-free HCV treatment in October. The release of the new drug is expected to drive down costs.
During the briefing, Gilead Sciences Vice President Coy Stout and two cured HCV patients argued that the drug's cost is less than that of a liver transplant.
More articles on gastroenterology:
Why do gastroenterologists need a GI-specific EMR system?
Is the MD/MBA combination the key to navigating healthcare today?
CRC test ColoMarker receives CE mark
Sovaldi is currently priced at approximately $1,000 a pill, a total of $84,000 or more for a full course of treatment. But, Gilead Sciences intends to release a new interferon-free HCV treatment in October. The release of the new drug is expected to drive down costs.
During the briefing, Gilead Sciences Vice President Coy Stout and two cured HCV patients argued that the drug's cost is less than that of a liver transplant.
More articles on gastroenterology:
Why do gastroenterologists need a GI-specific EMR system?
Is the MD/MBA combination the key to navigating healthcare today?
CRC test ColoMarker receives CE mark